

Questions about the newsletter? Write to [giorgio.barbareschi@eatg.org](mailto:giorgio.barbareschi@eatg.org)

## What's New?

### FIRST ROUND OF ECAB 2023: BARCELONA

On 31 March and 1 April EATG, **14 European Community Advisory Board (ECAB) Members met in Barcelona** with Gilead, ViiV Healthcare and Merck Sharpe and Dohme to discuss advancements in research and development around HIV treatment and prevention. Our meeting included **a site visit to BCN Checkpoint** to check out their very impressive community-based services.

### RBDCOV: F2F MEETING WITH EATG'S COMMUNITY ADVISORY PANEL IN GIRONA

On April 19th, the EATG team met face-to-face with the members of the **Community Advisory Panel (CAP)** for the RBDCOV project in Girona, Spain. After an internal meeting to discuss the CAP's current and future role within the project, we organised **a site visit to HIPRA's facilities** to receive the latest updates on the vaccine development and discuss how to strengthen community engagement in the project. In addition, at the end of March, the Committee for Medicinal Products for Human Use of the **EMA has recommended authorising HIPRA's COVID-19 vaccine, BIMERVAX®**, as a booster in people aged 16 years and above who have been vaccinated with a COVID-19 mRNA vaccine.

### BELONG: WHY PEOPLE LIVING WITH HIV MUST BE INCLUDED IN NON-HIV CLINICAL TRIALS - A VIRTUAL ROUNDTABLE DISCUSSION

On May 04th, EATG organised a **virtual roundtable** with the aim of creating a space to discuss why people living with HIV must be included in non-HIV clinical trials. The event brought together **52 stakeholders from Europe, North America and Africa**, including community representatives, industry, public health and research institution and regulatory agencies. After presenting EATG's position paper, three guest speakers discussed **the importance, the barriers and next steps needed** to include people living with HIV in clinical research of potentially life-extending or life-saving drugs and treatments for other health conditions and comorbidities.



The Patient Engagement Resource Centre (PERC) has been launched!

Click on the logo to find out more!

## WHAT'S NEXT?

- EATG **PROMise project poster** being presented at **AIDS Impact 2023**.
- **RBDCOV: A cartoon infographic** to explain how the vaccine works will be launched soon.
- Kick-off call for the newly formed **Liver Health Committee** on 23 May.



EU-PEARL

### EU-PEARL Project delivers final results!

Last month marked the end of the **EU-PEARL project**. EU-PEARL has been a 3.5-year collaboration between many stakeholders, including patients and community, where **EATG led the Patient Advisory Group**. The project had the overall aim to design a platform trial framework that can be used to coordinate multi-company/ multi-drug platform trials. Platform trials can provide patients with faster access and more effective treatments, due to their adaptive design.

Click on the logo to have a look at all the tools developed!



PiS WANTS YOU!

Want to join the **ECAB & Protocol Review Pools?**

Click here to apply!



SAVE THE DATE:  
EVENTS & CONFERENCES

- **AIDS Impact:** 12-14 June 2023, Stockholm, Sweden.
- **IAS:** 23-25 July, Brisbane, Australia.
- **EACS:** 18-21 October, Warsaw, Poland.
- **HepHIV:** 13-15 November, Madrid, Spain.

## Meet the PiS Member: Nicolas Gateau

### Who is Nicolas Gateau in a nutshell?

I am Nicolas Gateau, 41 years old, and I have been working since 2018 at Sidaction, an HIV programmes fundraiser in France.

I joined Sidaction first as manager of MSM prevention programmes and now as thematic manager, where I oversee a capacity-building programme about gender equality, mainly in West Africa. I joined the EATG in 2019 because I was attracted by the work of the European Community Advisory Board (ECAB), which is now part of the PiS programme.

### What is that you like most about PiS and what is from your perspective one of the main achievements of the programme?

From my perspective, the work accomplished by the ECAB has always played a pivotal role to ensure that the voices of PLHIV are heard by pharmaceutical companies and that they do not forget that drugs must first serve to improve the lives and well-being of all patients - especially women and trans people, who are often overlooked in clinical trials.

What I would like to highlight about PiS is the tenacity, thoroughness and expertise of all the people I met within the programme and especially during ECAB meetings. I learn so much from them and although this expertise may impress, it is what matters the most to me in this programme, especially when it is put at the service of PLHIV.



EATG member since **2019**, Nicolas is currently a member of the **Partners in Science Programme Committee**.